In 2019, the FDA has approved an extended indication for pembrolizumab as a first-line treatment in patients with metastatic NSCLC whose tumors had PD-L1 TPS ≥1%1,18,26. The gene discussed is CD274; the disease is non-small cell lung carcinoma.